Immix Biopharma (IMMX) Net Cash Flow (2021 - 2026)

Immix Biopharma has disclosed Net Cash Flow across 6 years of filings, most recently posting -$14.7 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$14.7 million, down 736.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.2 million (up 564.44% YoY), and the FY2025 annual result was $76.2 million, up 43272.74% from the prior year.
• Net Cash Flow came in at -$14.7 million for Q1 2026 at Immix Biopharma, down from $78.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $78.0 million in Q4 2025 to a low of -$14.7 million in Q1 2026.
• The 5-year median for Net Cash Flow is -$1.8 million (2025), against an average of $3.6 million.
• Across the five-year window, Net Cash Flow slumped 2016.24% in 2022 and jumped 4032.39% in 2025, its largest moves.
• Immix Biopharma's Net Cash Flow stood at -$3.5 million in 2022, then jumped by 39.54% to -$2.1 million in 2023, then grew by 5.73% to -$2.0 million in 2024, then surged by 4032.39% to $78.0 million in 2025, then plunged by 118.8% to -$14.7 million in 2026.
• The last three Net Cash Flow figures came in at -$14.7 million (Q1 2026), $78.0 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.